The state-of-play and future of antibody therapeutics

Advanced Drug Delivery Reviews

Volumn 122, Issue , 2017, Pages 2-19

  Elgundi, Zehra ^a   Reslan, Mouhamad ^a   Cruz, Esteban ^a   Sifniotis, Vicki ^a   Kayser, Veysel ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibody drug conjugates (ADC); Antibody engineering; Biobetters; Biologicals; Biosimilars; Bispecific antibodies; Degradation; Formulation; Manufacture; Monoclonal antibodies (mAbs); Stability; Therapeutic antibodies

Indexed keywords

CELL CULTURE; COMMERCE; CONVERGENCE OF NUMERICAL METHODS; COST EFFECTIVENESS; DEGRADATION; DEVELOPING COUNTRIES; MANUFACTURE; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

ANTIBODY ENGINEERING; ANTIBODY-DRUG CONJUGATES; BIOBETTERS; BIOLOGICALS; BIOSIMILARS; FORMULATION; MONOCLONAL ANTIBODIES (MABS); THERAPEUTIC ANTIBODIES;

COSTS;

ANTIBODY DRUG CONJUGATE; ATEZOLIZUMAB; BETA1A INTERFERON; BIOSIMILAR AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CAPLACIZUMAB; CLAZAKIZUMAB; DULIGOTUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRUTINIB; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; OCRELIZUMAB; OTELIXIZUMAB; TRASTUZUMAB; UBLITUXIMAB; ANTIBODY CONJUGATE;

ACUTE MYELOID LEUKEMIA; ADVANCED CANCER; BIOENGINEERING; BLADDER CANCER; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; DEAMINATION; DENATURATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG OXIDATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; MATHEMATICAL COMPUTING; MULTIPLE SCLEROSIS; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WORLD HEALTH ORGANIZATION; ECONOMICS; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; PROTEIN ENGINEERING;

EID: 85008199343     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.11.004     Document Type: Review

References (230)

1. Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. MAbs 7 (2015), 9–14.
2. Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov. Today 20 (2015), 838–847.
3. Drake, P.M., Rabuka, D., An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. Curr. Opin. Chem. Biol. 28 (2015), 174–180.
4. Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975), 495–497.
5. Kohler, G., Milstein, C., Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6 (1976), 511–519.
6. Li, W., Caberoy, N.B., New perspective for phage display as an efficient and versatile technology of functional proteomics. Appl. Microbiol. Biotechnol. 85 (2010), 909–919.
7. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986), 522–525.
8. Riechmann, L., Clark, M., Waldmann, H., Winter, G., Reshaping human antibodies for therapy. Nature 332 (1988), 323–327.
9. Lonberg, N., Human antibodies from transgenic animals. Nat. Biotechnol. 23 (2005), 1117–1125.
10. Scott, C.T., Mice with a human touch. Nat. Biotechnol. 25 (2007), 1075–1077.
11. Jakobovits, A., Amado, R., Yang, X., Roskos, L., Schwab, G., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 25 (2007), 1134–1143.
12. Huse, W.D., Sastry, L., Iverson, S.A., Kang, A.S., Alting-Mees, M., Burton, D.R., Benkovic, S.J., Lerner, R.A., Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246 (1989), 1275–1281.
13. McCafferty, J., Griffiths, A.D., Winter, G., Chiswell, D.J., Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 (1990), 552–554.
14. Barbas, C.F. III, Kang, A.S., Lerner, R.A., Benkovic, S.J., Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. 88 (1991), 7978–7982.
15. Schofield, D.J., Pope, A.R., Clementel, V., Buckell, J., Chapple, S.D.J., Clarke, K.F., Conquer, J.S., Crofts, A.M., Crowther, S.R.E., Dyson, M.R., Flack, G., Griffin, G.J., Hooks, Y., Howat, W.J., Kolb-Kokocinski, A., Kunze, S., Martin, C.D., Maslen, G.L., Mitchell, J.N., O'Sullivan, M., Perera, R.L., Roake, W., Shadbolt, S.P., Vincent, K.J., Warford, A., Wilson, W.E., Xie, J., Young, J.L., McCafferty, J., Application of phage display to high throughput antibody generation and characterization. Genome Biol., 8, 2007.
16. Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., Winter, G., By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 (1991), 581–597.
17. Barbas, C.F.I., Bain, J.D., Hoekstra, D.M., Lerner, R.A., Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. 89 (1992), 4457–4461.
18. Hoogenboom, H.R., Winter, G., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. 227 (1992), 381–388.
19. Hoogenboom, H.R., Griffiths, A.D., Johnson, K.S., Chiswell, D.J., Hudson, P., Winter, G., Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19 (1991), 4133–4137.
20. Davies, J., Riechmann, L., An antibody variable heavy domain with a lox-Cre site integrated into its coding region: bacterial recombination within a single polypeptide chain. FEBS Lett. 377 (1995), 92–96.
21. Harmsen, M.M., De Haard, H.J., Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77 (2007), 13–22.
22. Nuttall, S.D., Krishnan, U.V., Doughty, L., Pearson, K., Ryan, M.T., Hoogenraad, N.J., Hattarki, M., Carmichael, J.A., Irving, R.A., Hudson, P.J., Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur. J. Biochem. 270 (2003), 3543–3554.
23. Nakano, K., Kojima, T., Kasutani, K., Senoh, C., Natori, O., Ishii, S., Tsunoda, H., Hattori, K., Effective screening method of agonistic diabodies based on autocrine growth. J. Immunol. Methods 347 (2009), 31–35.
24. Mazor, Y., Van Blarcom, T., Mabry, R., Iverson, B.L., Georgiou, G., Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol. 25 (2007), 563–565.
25. Jespers, L.S., Roberts, A., Mahler, S.M., Winter, G., Hoogenboom, H.R., Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 12 (1994), 899–903.
26. Nixon, A.E., Sexton, D.J., Ladner, R.C., Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6 (2014), 73–85.
27. Daugherty, P.S., Chen, G., Olsen, M.J., Iverson, B.L., Georgiou, G., Antibody affinity maturation using bacterial surface display. Protein Eng. 11 (1998), 825–832.
28. Feldhaus, M.J., Siegel, R.W., Opresko, L.K., Coleman, J.R., Feldhaus, J.M., Yeung, Y.A., Cochran, J.R., Heinzelman, P., Colby, D., Swers, J., Graff, C., Wiley, H.S., Wittrup, K.D., Flow-cytometric isolation of human antibodies from a non immune Sacchromyces cerevisiae surface display library. Nat. Biotechnol. 21 (2003), 163–170.
29. Mottershead, D.G., Alfthan, K., Ojala, K., Takkinen, K., Oker-Blom, C., Baculoviral display of functional scFv and synthetic IgG-binding domains. Biochem. Biophys. Res. Commun. 275 (2000), 84–90.
30. Hanes, J., Schaffitzel, C., Knappik, A., Pluckthun, A., Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18 (2000), 1287–1292.
31. Georgiou, G., Ippolito, G.C., Beausang, J., Busse, C.E., Wardemann, H., Quake, S.R., The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol. 32 (2014), 158–168.
32. Ravn, U., Didelot, G., Venet, S., Ng, K.T., Gueneau, F., Rousseau, F., Calloud, S., Kosco-Vilbois, M., Fischer, N., Deep sequencing of phage display libraries to support antibody discovery. Methods 60 (2013), 99–110.
33. Mathonet, P., Ullman, C.G., The application of next generation sequencing to the understanding of antibody repertoires. Front. Immunol., 4, 2013.
34. Cheung, W.C., Beausoleil, S.A., Zhang, X., Sato, S., Schieferl, S.M., Wieler, J.S., Beaudet, J.G., Ramenani, R.K., Popova, L., Comb, M.J., Rush, J., Polakiewicz, R.D., A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 30 (2012), 447–452.
35. Reddy, S.T., Ge, X., Miklos, A.E., Hughes, R.A., Kang, S.H., Hoi, K.H., Chrysostomou, C., Hunicke-Smith, S.P., Iverson, B.L., Tucker, P.W., Ellington, A.D., Georgiou, G., Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 28 (2010), 965–969.
36. Ravn, U., Gueneau, F., Baerlocher, L., Osteras, M., Desmurs, M., Malinge, P., Magistrelli, G., Farinelli, L., Kosco-Vilbois, M.H., Fischer, N., By-passing in vitro screening–next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Res., 38, 2010, e193.
37. DeKosky, B.J., Ippolito, G.C., Deschner, R.P., Lavinder, J.J., Wine, Y., Rawlings, B.M., Varadarajan, N., Giesecke, C., Dorner, T., Andrews, S.F., Wilson, P.C., Hunicke-Smith, S.P., Willson, C.G., Ellington, A.D., Georgiou, G., High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol. 31 (2013), 166–169.
38. Saggy, I., Wine, Y., Shefet-Carasso, L., Nahary, L., Georgiou, G., Benhar, I., Antibody isolation from immunized animals: comparison of phage display and antibody discovery via V gene repertoire mining. Protein Eng. Des. Sel. 25 (2012), 539–549.
39. Lehmann-Horn, K., Kronsbein, H.C., Weber, M.S., Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther. Adv. Neurol. Disord. 6 (2013), 161–173.
40. Vazquez, A.M., Hernandez, A.M., Macias, A., Montero, E., Gomez, D.E., Alonso, D.F., Gabri, M.R., Gomez, R.E., Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front. Oncol., 2, 2012, 150.
41. Garrone, P., Djossou, O., Fossiez, F., Reyes, J., Ait-Yahia, S., Maat, C., Ho, S., Hauser, T., Dayer, J.M., Greffe, J., Miossec, P., Lebecque, S., Rousset, F., Banchereau, J., Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Mol. Immunol. 33 (1996), 649–658.
42. Hong, D.S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G.S., Piha-Paul, S., Wheler, J.J., Fu, S., Tsimberidou, A.M., Stecher, M., Mohanty, P., Simard, J., Kurzrock, R., MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 15 (2014), 656–666.
43. Kim, Y.S., Choi, B.W., Yang, S.W., Shin, S.M., Nam, S.W., Roh, Y.S., Lee, J.Y., Lee, K.J., Kim, Y.J., Kwon, J.-Y., Kim, D.-I., Biosimilars: challenges and path forward. Biotechnol. Bioprocess Eng. 19 (2014), 755–765.
44. Berghout, A., Clinical programs in the development of similar biotherapeutic products: rationale and general principles. Biologicals 39 (2011), 293–296.
45. Kudrin, A., Knezevic, I., Joung, J., Kang, H.-N., Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval. Biologicals 43 (2015), 1–10.
46. WHO, Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization (WHO) Expert Committee on Biological Standardization, 2009.
47. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Guideline on Developement, Production, Characterisation and Specification for Monoclonal Antibodies and Related Products. 2008, European Medicines Agency, London (UK).
48. Committee for Medicinal Products for Human Use, Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-clinical and Clinical Issues. 2012, European Medicines Agency, London (UK).
49. Committee for Medicinal Products for Human Use, Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. 2012, European Medicines Agency, London (UK).
50. Committee for Medicinal Products for Human Use, Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues. 2014, European Medicines Agency, London (UK).
51. Committee for Medicinal Products for Human Use, Guideline on Similar Biological Medicinal Products. 2014, European Medicines Agency, London (UK).
52. Committee for Medicinal Products for Human Use, Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Quality Issues (Revision 1). 2014, European Medicines Agency, London (UK).
53. Food and Drug Administration, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015, Guidance for Industry, Silver Spring (MD).
54. Food and Drug Administration, Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. 2015, Guidance for Industry, Silver Spring (MD).
55. Food and Drug Administration, Guidance for Industry, Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (Draft Guidance). 2014.
56. Thimmaraju, P.K., Rakshambikai, R., Farista, R., Juluru, K., Legislations on biosimilar interchangeability in the US and EU – developments far from visibility. Generics Biosimilars Initiative, 2015 http://www.gabionline.net/Sponsored-Articles/Legislations-on-biosimilar-interchangeability-in-the-US-and-EU-developments-far-from-visibility.
57. Smits, L.J., Derikx, L.A., de Jong, D.J., Boshuizen, R.S., van Esch, A.A., Drenth, J.P., Hoentjen, F., Clinical outcomes following a switch from remicade to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J. Crohns Colitis 10 (2016), 1287–1293.
58. Brown, J., Kudrin, A., Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals 44 (2016), 257–266.
59. de Labry, A.O., Giménez, E., Lindner, L., García, L., Espín, J., Rovira, J., Biosimilars in the European market. Generics Biosimilars Initiative J. (GaBI J.) 2 (2013), 30–35.
60. Blackstone, E.A., Joseph, P.F., The economics of biosimilars. Am. Health Drug Benefits 6 (2013), 469–478.
61. Chames, P., Van Regenmortel, M., Weiss, E., Baty, D., Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157 (2009), 220–233.
62. Niwa, R., Satoh, M., The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. J. Pharm. Sci. 104 (2015), 930–941.
63. Evans, J.B., Syed, B.A., From the analyst's couch: next-generation antibodies. Nat. Rev. Drug Discov. 13 (2014), 413–414.
64. Shpilberg, O., Jackisch, C., Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br. J. Cancer 109 (2013), 1556–1561.
65. Derer, S., Kellner, C., Berger, S., Valerius, T., Peipp, M., Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol. Biol. 907 (2012), 519–536.
66. Beck, A., Reichert, J.M., Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 4 (2012), 419–425.
67. Sachdeva, M., Dhingra, S., Obinutuzumab: a FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia. Int. J. Appl. Basic Med. Res. 5 (2015), 54–57.
68. Ratner, M., Genentech's glyco-engineered antibody to succeed Rituxan. Nat. Biotechnol., 32, 2014 (6 +).
69. Subramaniam, J.M., Whiteside, G., McKeage, K., Croxtall, J.C., Mogamulizumab: first global approval. Drugs 72 (2012), 1293–1298.
70. Kakkar, A.K., Balakrishnan, S., Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation. J. Oncol. Pharm. Pract. 21 (2015), 358–363.
71. Liu, S.D., Chalouni, C., Young, J.C., Junttila, T.T., Sliwkowski, M.X., Lowe, J.B., Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol. Res. 3 (2015), 173–183.
72. Mizushima, T., Yagi, H., Takemoto, E., Shibata-Koyama, M., Isoda, Y., Iida, S., Masuda, K., Satoh, M., Kato, K., Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16 (2011), 1071–1080.
73. Preithner, S., Elm, S., Lippold, S., Locher, M., Wolf, A., da Silva, A.J., Baeuerle, P.A., Prang, N.S., High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol. Immunol. 43 (2006), 1183–1193.
74. Zhang, N., Liu, L., Dan Dumitru, C., Cummings, N.R.H., Cukan, M., Jiang, Y., Li, Y., Li, F., Mitchell, T., Mallem, M.R., Ou, Y., Patel, R.N., Vo, K., Wang, H., Burnina, I., Choi, B.-K., Huber, H.E., Stadheim, T.A., Zha, D., Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3 (2011), 289–298.
75. Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J.A., Presta, L.G., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 (2001), 6591–6604.
76. Lazar, G.A., Dang, W., Karki, S., Vafa, O., Peng, J.S., Hyun, L., Chan, C., Chung, H.S., Eivazi, A., Yoder, S.C., Vielmetter, J., Carmichael, D.F., Hayes, R.J., Dahiyat, B.I., Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. 103 (2006), 4005–4010.
77. Stavenhagen, J.B., Gorlatov, S., Tuaillon, N., Rankin, C.T., Li, H., Burke, S., Huang, L., Vijh, S., Johnson, S., Bonvini, E., Koenig, S., Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 67 (2007), 8882–8890.
78. Jung, S.T., Reddy, S.T., Kang, T.H., Borrok, M.J., Sandlie, I., Tucker, P.W., Georgiou, G., Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. 107 (2010), 604–609.
79. Sazinsky, S.L., Ott, R.G., Silver, N.W., Tidor, B., Ravetch, J.V., Wittrup, K.D., Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. 105 (2008), 20167–20172.
80. Borrok, M.J., Jung, S.T., Kang, T.H., Monzingo, A.F., Georgiou, G., Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7 (2012), 1596–1602.
81. Stewart, R., Thom, G., Levens, M., Guler-Gane, G., Holgate, R., Rudd, P.M., Webster, C., Jermutus, L., Lund, J., A variant human IgG1-Fc mediates improved ADCC. Protein Eng. Des. Sel. 24 (2011), 671–678.
82. Kayser, V., Chennamsetty, N., Voynov, V., Forrer, K., Helk, B., Trout, B.L., Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol. J. 6 (2011), 38–44.
83. Mimura, Y., Church, S., Ghirlando, R., Ashton, P.R., Dong, S., Goodall, M., Lund, J., Jefferis, R., The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37 (2000), 697–706.
84. Zaro, J.L., Mylotarg: revisiting its clinical potential post-withdrawal. Wang, J., Shen, W.-C., Zaro, J.L., (eds.) Antibody-Drug Conjugates, 2015, Springer International Publishing, 179–190.
85. Burrows, F.J., Thorpe, P.E., Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. 90 (1993), 8996–9000.
86. Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G.F., Boyle, R.W., Neri, D., A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 104 (2011), 1106–1115.
87. Visintin, A., Knowlton, K., Tyminski, E., Lin, C.I., Zheng, X., Marquette, K., Jain, S., Tchistiakova, L., Li, D., O'Donnell, C.J., Maderna, A., Cao, X., Dunn, R., Snyder, W.B., Abraham, A.K., Leal, M., Shetty, S., Barry, A., Zawel, L., Coyle, A.J., Dvorak, H.F., Jaminet, S.C., Novel anti-TM4SF1 antibody-drug conjugates with activity against tumor cells and tumor vasculature. Mol. Cancer Ther. 14 (2015), 1868–1876.
88. Ostermann, E., Garin-Chesa, P., Heider, K.H., Kalat, M., Lamche, H., Puri, C., Kerjaschki, D., Rettig, W.J., Adolf, G.R., Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14 (2008), 4584–4592.
89. Quail, D., Joyce, J., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19 (2013), 1423–1437.
90. Pettit, G.R., Kamano, Y., Herald, C.L., Tuinman, A.A., Boettner, F.E., Kizu, H., Schmidt, J.M., Baczynskyj, L., Tomer, K.B., Bontems, R.J., The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc. 109 (1987), 6883–6885.
91. Maiese, W.M., Lechevalier, M.P., Lechevalier, H.A., Korshalla, J., Kuck, N., Fantini, A., Wildey, M.J., Thomas, J., Greenstein, M., Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J. Antibiot. 42 (1989), 558–563.
92. Cassady, J.M., Chan, K.K., Floss, H.G., Leistner, E., Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. 52 (2004), 1–26.
93. Chari, R.V., Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41 (2008), 98–107.
94. Doronina, S.O., Mendelsohn, B.A., Bovee, T.D., Cerveny, C.G., Alley, S.C., Meyer, D.L., Oflazoglu, E., Toki, B.E., Sanderson, R.J., Zabinski, R.F., Wahl, A.F., Senter, P.D., Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17 (2006), 114–124.
95. Jerjian, T.V., Glode, A.E., Thompson, L.A., O'Bryant, C.L., Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy. Pharmacotherapy 36 (2016), 99–116.
96. Elgersma, R.C., Coumans, R.G., Huijbregts, T., Menge, W.M., Joosten, J.A., Spijker, H.J., de Groot, F.M., van der Lee, M.M., Ubink, R., van den Dobbelsteen, D.J., Egging, D.F., Dokter, W.H., Verheijden, G.F., Lemmens, J.M., Timmers, C.M., Beusker, P.H., Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol. Pharm. 12 (2015), 1813–1835.
97. Hartley, J.A., The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 20 (2011), 733–744.
98. Koblinski, J.E., Ahram, M., Sloane, B.F., Unraveling the role of proteases in cancer. Clin. Chim. Acta 291 (2000), 113–135.
99. Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace, D.F., DeBlanc, R.L., Gearing, R.P., Bovee, T.D., Siegall, C.B., Francisco, J.A., Wahl, A.F., Meyer, D.L., Senter, P.D., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21 (2003), 778–784.
100. Vaklavas, C., Forero-Torres, A., Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther. Adv. Hematol. 3 (2012), 209–225.
101. Bendell, J., Saleh, M., Rose, A.A., Siegel, P.M., Hart, L., Sirpal, S., Jones, S., Green, J., Crowley, E., Simantov, R., Keler, T., Davis, T., Vahdat, L., Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 32 (2014), 3619–3625.
102. Erickson, H.K., Park, P.U., Widdison, W.C., Kovtun, Y.V., Garrett, L.M., Hoffman, K., Lutz, R.J., Goldmacher, V.S., Blattler, W.A., Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66 (2006), 4426–4433.
103. Alley, S., Zhang, X., Okeley, N., Anderson, M., Oflazoglu, E., Stone, I., Law, C.-L., Senter, P., Benjamin, D., Effects of linker chemistry on tumor targeting by anti-CD70 antibody-drug conjugates. Cancer Res., 67, 2007, 916.
104. Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I.E., Vogel, C.L., Burris Iii, H.A., LoRusso, P.M., Yi, J.H., Saad, O., Tong, B., Chu, Y.W., Holden, S., Joshi, A., Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69 (2012), 1229–1240.
105. Polson, A.G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F.J., Eaton, D., Elkins, K., Elliott, J.M., Frantz, G., Fuji, R.N., Gray, A., Harden, K., Ingle, G.S., Kljavin, N.M., Koeppen, H., Nelson, C., Prabhu, S., Raab, H., Ross, S., Slaga, D.S., Stephan, J.P., Scales, S.J., Spencer, S.D., Vandlen, R., Wranik, B., Yu, S.F., Zheng, B., Ebens, A., Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69 (2009), 2358–2364.
106. Erickson, H.K., Lewis Phillips, G.D., Leipold, D.D., Provenzano, C.A., Mai, E., Johnson, H.A., Gunter, B., Audette, C.A., Gupta, M., Pinkas, J., Tibbitts, J., The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther. 11 (2012), 1133–1142.
107. Lyon, R.P., Meyer, D.L., Setter, J.R., Senter, P.D., Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues. Methods Enzymol. 502 (2012), 123–138.
108. Brun, M.P., Gauzy-Lazo, L., Protocols for lysine conjugation. Methods Mol. Biol. 1045 (2013), 173–187.
109. Behrens, C.R., Ha, E.H., Chinn, L.L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., Liao-Chan, S., Wong, T., Melnick, J., Theunissen, J.W., Flory, M.R., Houser, D., Venstrom, K., Levashova, Z., Sauer, P., Migone, T.S., van der Horst, E.H., Halcomb, R.L., Jackson, D.Y., Antibody-drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol. Pharm. 12 (2015), 3986–3998.
110. Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S., Chen, Y., Simpson, M., Tsai, S.P., Dennis, M.S., Lu, Y., Meng, Y.G., Ng, C., Yang, J., Lee, C.C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S.D., Lee Wong, W., Lowman, H.B., Vandlen, R., Sliwkowski, M.X., Scheller, R.H., Polakis, P., Mallet, W., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26 (2008), 925–932.
111. Axup, J.Y., Bajjuri, K.M., Ritland, M., Hutchins, B.M., Kim, C.H., Kazane, S.A., Halder, R., Forsyth, J.S., Santidrian, A.F., Stafin, K., Lu, Y., Tran, H., Seller, A.J., Biroc, S.L., Szydlik, A., Pinkstaff, J.K., Tian, F., Sinha, S.C., Felding-Habermann, B., Smider, V.V., Schultz, P.G., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. 109 (2012), 16101–16106.
112. Zimmerman, E.S., Heibeck, T.H., Gill, A., Li, X., Murray, C.J., Madlansacay, M.R., Tran, C., Uter, N.T., Yin, G., Rivers, P.J., Yam, A.Y., Wang, W.D., Steiner, A.R., Bajad, S.U., Penta, K., Yang, W., Hallam, T.J., Thanos, C.D., Sato, A.K., Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 25 (2014), 351–361.
113. Sochaj, A.M., Swiderska, K.W., Otlewski, J., Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol. Adv. 33 (2015), 775–784.
114. van Geel, R., Wijdeven, M.A., Heesbeen, R., Verkade, J.M., Wasiel, A.A., van Berkel, S.S., van Delft, F.L., Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates. Bioconjug. Chem. 26 (2015), 2233–2242.
115. Nisonoff, A., Rivers, M.M., Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 93 (1961), 460–462.
116. Staerz, U.D., Bevan, M.J., Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc. Natl. Acad. Sci. 83 (1986), 1453–1457.
117. Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S.B., Born, T., Retter, M., Manchulenko, K., Sweet, H., Foltz, I.N., Wittekind, M., Yan, W., Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285 (2010), 19637–19646.
118. Von Kreudenstein, T.S., Escobar-Carbrera, E., Lario, P.I., D'Angelo, I., Brault, K., Kelly, J., Durocher, Y., Baardsnes, J., Woods, R.J., Xie, M.H., Girod, P.A., Suits, M.D., Boulanger, M.J., Poon, D.K., Ng, G.Y., Dixit, S.B., Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs 5 (2013), 646–654.
119. Lewis, S.M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H.L., Guntas, G., Leaver-Fay, A., Smith, E.M., Ho, C., Hansen-Estruch, C., Chamberlain, A.K., Truhlar, S.M., Conner, E.M., Atwell, S., Kuhlman, B., Demarest, S.J., Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. 32 (2014), 191–198.
120. Ridgway, J.B., Presta, L.G., Carter, P., ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. Des. Sel. 9 (1996), 617–621.
121. Schaefer, W., Regula, J.T., Bahner, M., Schanzer, J., Croasdale, R., Durr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., Schwaiger, M., Stubenrauch, K.G., Sustmann, C., Thomas, M., Scheuer, W., Klein, C., Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. 108 (2011), 11187–11192.
122. Rossi, E.A., Goldenberg, D.M., Cardillo, T.M., McBride, W.J., Sharkey, R.M., Chang, C.H., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. 103 (2006), 6841–6846.
123. Rossi, E.A., Goldenberg, D.M., Chang, C.H., The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug. Chem. 23 (2012), 309–323.
124. Davis, J.H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.M., Huston, J.S., SEED bodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23 (2010), 195–202.
125. Zeidler, R., Mysliwietz, J., Csanady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., Lindhofer, H., The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br. J. Cancer 83 (2000), 261–266.
126. Ott, M.G., Marme, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M.M., Linke, R., Seimetz, D., Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int. J. Cancer 130 (2012), 2195–2203.
127. Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., Baeuerle, P.A., BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today 10 (2005), 1237–1244.
128. Baeuerle, P.A., Kufer, P., Bargou, R., BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 11 (2009), 22–30.
129. Newman, M.J., Benani, D.J., A review of blinatumomab, a novel immunotherapy. J. Oncol. Pharm. Pract. 22 (2016), 639–645.
130. Topp, M.S., Gokbuget, N., Stein, A.S., Zugmaier, G., O'Brien, S., Bargou, R.C., Dombret, H., Fielding, A.K., Heffner, L., Larson, R.A., Neumann, S., Foa, R., Litzow, M., Ribera, J.M., Rambaldi, A., Schiller, G., Bruggemann, M., Horst, H.A., Holland, C., Jia, C., Maniar, T., Huber, B., Nagorsen, D., Forman, S.J., Kantarjian, H.M., Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16 (2015), 57–66.
131. Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., Yang, Y., Jin, L., Ciccarone, V., Moore, P.A., Koenig, S., Bonvini, E., Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 399 (2010), 436–449.
132. Moore, P.A., Zhang, W., Rainey, G.J., Burke, S., Li, H., Huang, L., Gorlatov, S., Veri, M.C., Aggarwal, S., Yang, Y., Shah, K., Jin, L., Zhang, S., He, L., Zhang, T., Ciccarone, V., Koenig, S., Bonvini, E., Johnson, S., Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117 (2011), 4542–4551.
133. Kipriyanov, S.M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.W., Matys, E.R., Little, M., Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293 (1999), 41–56.
134. McAleese, F., Eser, M., RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol. 8 (2012), 687–695.
135. Liddy, N., Bossi, G., Adams, K.J., Lissina, A., Mahon, T.M., Hassan, N.J., Gavarret, J., Bianchi, F.C., Pumphrey, N.J., Ladell, K., Gostick, E., Sewell, A.K., Lissin, N.M., Harwood, N.E., Molloy, P.E., Li, Y., Cameron, B.J., Sami, M., Baston, E.E., Todorov, P.T., Paston, S.J., Dennis, R.E., Harper, J.V., Dunn, S.M., Ashfield, R., Johnson, A., McGrath, Y., Plesa, G., June, C.H., Kalos, M., Price, D.A., Vuidepot, A., Williams, D.D., Sutton, D.H., Jakobsen, B.K., Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18 (2012), 980–987.
136. Schaefer, G., Haber, L., Crocker, L.M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C.V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G.D., Prell, R.A., Danilenko, D.M., Franke, Y., Stephan, J.P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M.X., Fuh, G., Eigenbrot, C., A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20 (2011), 472–486.
137. Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.R., Santora, L., Davis-Taber, R., Kunes, Y., Fung, E., Schwartz, A., Sakorafas, P., Gu, J., Tarcsa, E., Murtaza, A., Ghayur, T., Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25 (2007), 1290–1297.
138. Conrath, K.E., Lauwereys, M., Galleni, M., Matagne, A., Frere, J.M., Kinne, J., Wyns, L., Muyldermans, S., Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 45 (2001), 2807–2812.
139. Jones, S.D., Seymour, P., Levine, H.L., CMC Activities for Development of MAbs. 2010, Contract Pharma, 60–63.
140. Chartrain, M., Chu, L., Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies. Curr. Pharm. Biotechnol. 9 (2008), 447–467.
141. Robinson, M.P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T.J., Tuckey, C., Riggs, P.D., Colussi, P.A., Noren, C.J., Taron, C.H., DeLisa, M.P., Berkmen, M., Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nat. Commun., 6, 2015, 8072.
142. Jung, S.T., Kelton, W., Kang, T.H., Ng, D.T., Andersen, J.T., Sandlie, I., Sarkar, C.A., Georgiou, G., Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcgammaRIIa affinity and selectivity. ACS Chem. Biol. 8 (2013), 368–375.
143. Li, H., Sethuraman, N., Stadheim, T.A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.K., Cook, W.J., Cukan, M., Houston-Cummings, N.R., Davidson, R., Gong, B., Hamilton, S.R., Hoopes, J.P., Jiang, Y., Kim, N., Mansfield, R., Nett, J.H., Rios, S., Strawbridge, R., Wildt, S., Gerngross, T.U., Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 24 (2006), 210–215.
144. Potgieter, T.I., Kersey, S.D., Mallem, M.R., Nylen, A.C., d'Anjou, M., Antibody expression kinetics in glycoengineered Pichia pastoris. Biotechnol. Bioeng. 106 (2010), 918–927.
145. Ye, J., Ly, J., Watts, K., Hsu, A., Walker, A., McLaughlin, K., Berdichevsky, M., Prinz, B., Sean Kersey, D., d'Anjou, M., Pollard, D., Potgieter, T., Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol. Prog. 27 (2011), 1744–1750.
146. Ma, J.K., Lehner, T., Stabila, P., Fux, C.I., Hiatt, A., Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants. Eur. J. Immunol. 24 (1994), 131–138.
147. De Muynck, B., Navarre, C., Boutry, M., Production of antibodies in plants: status after twenty years. Plant Biotechnol. J. 8 (2010), 529–563.
148. Moussavou, G., Ko, K., Lee, J.H., Choo, Y.K., Production of monoclonal antibodies in plants for cancer immunotherapy. Biomed. Res. Int., 2015, 2015, 306164.
149. Grohs, B.M., Niu, Y., Veldhuis, L.J., Trabelsi, S., Garabagi, F., Hassell, J.A., McLean, M.D., Hall, J.C., Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. J. Agric. Food Chem. 58 (2010), 10056–10063.
150. Bandaranayake, A.D., Almo, S.C., Recent advances in mammalian protein production. FEBS Lett. 588 (2014), 253–260.
151. Browne, S.M., Al-Rubeai, M., Selection methods for high-producing mammalian cell lines. Trends Biotechnol. 25 (2007), 425–432.
152. Shi, S., Condon, R.G., Deng, L., Saunders, J., Hung, F., Tsao, Y.S., Liu, Z., A high-throughput automated platform for the development of manufacturing cell lines for protein therapeutics. J. Vis. Exp., 55, 2011, e3010, 10.3791/3010.
153. Chu, L., Robinson, D.K., Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12 (2001), 180–187.
154. Liu, H.F., Ma, J., Winter, C., Bayer, R., Recovery and purification process development for monoclonal antibody production. MAbs 2 (2010), 480–499.
155. Birch, J.R., Racher, A.J., Antibody production. Adv. Drug Deliv. Rev. 58 (2006), 671–685.
156. Fahrner, R.L., Knudsen, H.L., Basey, C.D., Galan, W., Feuerhelm, D., Vanderlaan, M., Blank, G.S., Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 18 (2001), 301–327.
157. Schwart, W., Judd, D., Wysocki, M., Guerrier, L., Birck-Wilson, E., Boschetti, E., Comparison of hydrophobic charge induction chromatography with affinity chromatography on protein A for harvest and purification of antibodies. J. Chromatogr. A 908 (2001), 251–263.
158. van Reis, R., Gadam, S., Frautschy, L.N., Orlando, S., Goodrich, E.M., Saksena, S., Kuriyel, R., Simpson, C.M., Pearl, S., Zydney, A.L., High performance tangential flow filtration. Biotechnol. Bioeng. 56 (1997), 71–82.
159. Lebreton, B., Brown, A., van Reis, R., Application of high-performance tangential flow filtration (HPTFF) to the purification of a human pharmaceutical antibody fragment expressed in Escherichia coli. Biotechnol. Bioeng. 100 (2008), 964–974.
160. Arakawa, T., Futatsumori-Sugai, M., Tsumoto, K., Kita, Y., Sato, H., Ejima, D., MEP HyperCel chromatography II: binding, washing and elution. Protein Expr. Purif. 71 (2010), 168–173.
161. Manzke, O., Tesch, H., Diehl, V., Bohlen, H., Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J. Immunol. Methods 208 (1997), 65–73.
162. Nagorsen, D., Kufer, P., Baeuerle, P.A., Bargou, R., Blinatumomab: a historical perspective. Pharmacol. Ther. 136 (2012), 334–342.
163. Ducry, L., Challenges in the development and manufacturing of antibody-drug conjugates. Methods Mol. Biol. 899 (2012), 489–497.
164. Rader, R.A., Bioprocessing Challenges of Antibody–Drug Conjugates. 2014, BioProcess International.
165. Scanlan, C., Gousseinov, E., Becerra-Artega, A., Waghmare, R., Challenges and Strategies for the Downstream Processing of BiSpecific Antibodies (BsAbs). Journal of Antibody-Drug Conjugates, 2014, InPress Media Group.
166. Joubert, M.K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M.P., Goletz, T.J., Kerwin, B.A., Chirmule, N., Narhi, L.O., Jawa, V., Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J. Biol. Chem. 287 (2012), 25266–25279.
167. Hermeling, S., Crommelin, D.J., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 (2004), 897–903.
168. Rehder, D.S., Chelius, D., McAuley, A., Dillon, T.M., Xiao, G., Crouse-Zeineddini, J., Vardanyan, L., Perico, N., Mukku, V., Brems, D.N., Matsumura, M., Bondarenko, P.V., Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 47 (2008), 2518–2530.
169. Daugherty, A.L., Mrsny, R.J., Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 58 (2006), 686–706.
170. Yan, Y., Wei, H., Fu, Y., Jusuf, S., Zeng, M., Ludwig, R., Krystek, S.R., Chen, G., Tao, L., Das, T.K., Isomerization and oxidation in the complementarity-determining regions of a monoclonal antibody: a study of the modification–structure–function correlations by hydrogen–deuterium exchange mass spectrometry. Anal. Chem. 88 (2016), 2041–2050.
171. Moorthy, B., Xie, B., Moussa, E., Iyer, L., Chandrasekhar, S., Panchal, J., Topp, E., Structure of monoclonal antibodies. Rosenberg, A., Demeule, B., (eds.) Biobetters, 2015, Springer, New York, 81–89.
172. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B.L., Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. 106 (2009), 11937–11942.
173. Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., Trout, B.L., Prediction of aggregation prone regions of therapeutic proteins. J. Phys. Chem. B 114 (2010), 6614–6624.
174. Courtois, F., Schneider, C.P., Agrawal, N.J., Trout, B.L., Rational design of biobetters with enhanced stability. J. Pharm. Sci. 104 (2015), 2433–2440.
175. Ahmadi, M., Bryson, C.J., Cloake, E.A., Welch, K., Filipe, V., Romeijn, S., Hawe, A., Jiskoot, W., Baker, M.P., Fogg, M.H., Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm. Res. 32 (2015), 1383–1394.
176. Bessa, J., Boeckle, S., Beck, H., Buckel, T., Schlicht, S., Ebeling, M., Kiialainen, A., Koulov, A., Boll, B., Weiser, T., Singer, T., Rolink, A.G., Iglesias, A., The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm. Res. 32 (2015), 2344–2359.
177. Manning, M.C., Chou, D.K., Murphy, B.M., Payne, R.W., Katayama, D.S., Stability of protein pharmaceuticals: an update. Pharm. Res. 27 (2010), 544–575.
178. Sahin, E., Grillo, A.O., Perkins, M.D., Roberts, C.J., Comparative effects of pH and ionic strength on protein–protein interactions, unfolding, and aggregation for IgG1 antibodies. J. Pharm. Sci. 99 (2010), 4830–4848.
179. Arosio, P., Rima, S., Morbidelli, M., Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates. Pharm. Res. 30 (2013), 641–654.
180. Telikepalli, S.N., Kumru, O.S., Kalonia, C., Esfandiary, R., Joshi, S.B., Middaugh, C.R., Volkin, D.B., Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J. Pharm. Sci. 103 (2014), 796–809.
181. Depreter, F., Pilcer, G., Amighi, K., Inhaled proteins: challenges and perspectives. Int. J. Pharm. 447 (2013), 251–280.
182. Kayser, V., Chennamsetty, N., Voynov, V., Helk, B., Forrer, K., Trout, B.L., Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J. Pharm. Sci. 100 (2011), 2526–2542.
183. Kim, N., Remmele, R.L. Jr., Liu, D., Razinkov, V.I., Fernandez, E.J., Roberts, C.J., Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Biophys. Chem. 172 (2013), 26–36.
184. Wu, H., Kroe-Barrett, R., Singh, S., Robinson, A.S., Roberts, C.J., Competing aggregation pathways for monoclonal antibodies. FEBS Lett. 588 (2014), 936–941.
185. Mehta, S.B., Bee, J.S., Randolph, T.W., Carpenter, J.F., Partial unfolding of a monoclonal antibody: role of a single domain in driving protein aggregation. Biochemistry 53 (2014), 3367–3377.
186. Razinkov, V.I., Treuheit, M.J., Becker, G.W., Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools. J. Biomol. Screen. 20 (2015), 468–483.
187. Liu, H., Gaza-Bulseco, G., Sun, J., Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J. Chromatogr. B 837 (2006), 35–43.
188. Vlasak, J., Ionescu, R., Fragmentation of monoclonal antibodies. MAbs 3 (2011), 253–263.
189. Harris, R.J., Kabakoff, B., Macchi, F.D., Shen, F.J., Kwong, M., Andya, J.D., Shire, S.J., Bjork, N., Totpal, K., Chen, A.B., Identification of multiple sources of charge heterogeneity in a recombinant antibody. J. Chromatogr. B Biomed. Sci. Appl. 752 (2001), 233–245.
190. Liu, H., Gaza-Bulseco, G., Chumsae, C., Glutamine deamidation of a recombinant monoclonal antibody. Rapid Commun. Mass Spectrom. 22 (2008), 4081–4088.
191. Zhang, Y.T., Hu, J., Pace, A.L., Wong, R., Wang, Y.J., Kao, Y.-H., Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J. Chromatogr. B 965 (2014), 65–71.
192. Pace, A.L., Wong, R.L., Zhang, Y.T., Kao, Y.-H., Wang, Y.J., Asparagine deamidation dependence on buffer type, pH, and temperature. J. Pharm. Sci. 102 (2013), 1712–1723.
193. Yi, L., Beckley, N., Gikanga, B., Zhang, J., Wang, Y.J., Chih, H.-W., Sharma, V.K., Isomerization of Asp–Asp motif in model peptides and a monoclonal antibody fab fragment. J. Pharm. Sci. 102 (2013), 947–959.
194. Timm, V., Gruber, P., Wasiliu, M., Lindhofer, H., Chelius, D., Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies. J. Chromatogr. B 878 (2010), 777–784.
195. Huang, L., Lu, J., Wroblewski, V.J., Beals, J.M., Riggin, R.M., In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal. Chem. 77 (2005), 1432–1439.
196. Sreedhara, A., Yin, J., Joyce, M., Lau, K., Wecksler, A.T., Deperalta, G., Yi, L., John Wang, Y., Kabakoff, B., Kishore, R.S.K., Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. Eur. J. Pharm. Biopharm. 100 (2016), 38–46.
197. Sreedhara, A., Lau, K., Li, C., Hosken, B., Macchi, F., Zhan, D., Shen, A., Steinmann, D., Schöneich, C., Lentz, Y., Role of Surface Exposed Tryptophan as Substrate Generators for the Antibody Catalyzed Water Oxidation Pathway. Mol. Pharm. 10 (2013), 278–288.
198. Torosantucci, R., Schöneich, C., Jiskoot, W., Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm. Res. 31 (2014), 541–553.
199. Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., Ionescu, R., Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol. Immunol. 48 (2011), 860–866.
200. Wang, W., Singh, S., Zeng, D.L., King, K., Nema, S., Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007), 1–26.
201. Yan, B., Yates, Z., Balland, A., Kleemann, G.R., Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage. J. Biol. Chem. 284 (2009), 35390–35402.
202. Wei, Z., Feng, J., Lin, H.-Y., Mullapudi, S., Bishop, E., Tous, G.I., Casas-Finet, J., Hakki, F., Strouse, R., Schenerman, M.A., Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal. Chem. 79 (2007), 2797–2805.
203. Wilson, C.J., Rational protein design: developing next-generation biological therapeutics and nanobiotechnological tools. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7 (2015), 330–341.
204. Cerda-Costa, N., Esteras-Chopo, A., Aviles, F.X., Serrano, L., Villegas, V., Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates. J. Mol. Biol., 366, 2007, 1351.
205. de Groot, N., Pallares, I., Aviles, F., Vendrell, J., Ventura, S., Prediction of “hot spots” of aggregation in disease-linked polypeptides. BMC Struct. Biol., 5, 2005, 18.
206. Ogmen, U., Keskin, O., Aytuna, S., Nussinoiv, R., Gursoy, A., PRISM: protein interactions by structural matching. Nucleic Acids Res. 33 (2005), W331–W336.
207. Tartaglia, G.G., Vendruscolo, M., The Zyggregator method for predicting protein aggregation propensities. Chem. Soc. Rev. 37 (2008), 1395–1401.
208. Trovato, A., Seno, F., Tosatto, S.C.E., The PASTA server for protein aggregation prediction. Protein Eng. Des. Sel., 2007, gzm042.
209. Tartaglia, G.G., Cavalli, A., Pellarin, R., Caflisch, A., Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci. 14 (2005), 2723–2734.
210. Wang, X., Das, T.K., Singh, S.K., Kumar, S., Potential aggregation prone regions in biotherapeutics. MAbs 1 (2009), 254–267.
211. Angarica, V.E., Sancho, J., Protein dynamics governed by interfaces of high polarity and low packing density. PLoS ONE, 7, 2012, e48212.
212. Zambrano, R., Jamroz, M., Szczasiuk, A., Pujols, J., Kmiecik, S., Ventura, S., AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures. Nucleic Acids Res. 43 (2015), W306–W313.
213. Schweizer, D., Serno, T., Goepferich, A., Controlled release of therapeutic antibody formats. Eur. J. Pharm. Biopharm. 88 (2014), 291–309.
214. Karow, A.R., Bahrenburg, S., Garidel, P., Buffer capacity of biologics - from buffer salts to buffering by antibodies. Biotechnol. Prog. 29 (2013), 480–492.
215. Chang, L., Shepherd, D., Sun, J., Tang, X., Pikal, M.J., Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 94 (2005), 1445–1455.
216. Platts, L., Falconer, R.J., Controlling protein stability: mechanisms revealed using formulations of arginine, glycine and guanidinium HCl with three globular proteins. Int. J. Pharm. 486 (2015), 131–135.
217. Ohtake, S., Kita, Y., Arakawa, T., Interactions of formulation excipients with proteins in solution and in the dried state. Adv. Drug Deliv. Rev. 63 (2011), 1053–1073.
218. Yang, M.X., Shenoy, B., Disttler, M., Patel, R., McGrath, M., Pechenov, S., Margolin, A.L., Crystalline monoclonal antibodies for subcutaneous delivery. Proc. Natl. Acad. Sci. 100 (2003), 6934–6939.
219. Schweizer, D., Schonhammer, K., Jahn, M., Gopferich, A., Protein-polyanion interactions for the controlled release of monoclonal antibodies. Biomacromolecules 14 (2013), 75–83.
220. Grainger, D.W., Controlled-release and local delivery of therapeutic antibodies. Expert. Opin. Biol. Ther. 4 (2004), 1029–1044.
221. Shimizu, M., Miwa, Y., Hashimoto, K., Goto, A., Encapsulation of chicken egg yolk immunoglobulin G (IgY) by liposomes. Biosci. Biotechnol. Biochem. 57 (1993), 1445–1449.
222. Li, X.Y., Jin, L.J., McAllister, T.A., Stanford, K., Xu, J.Y., Lu, Y.N., Zhen, Y.H., Sun, Y.X., Xu, Y.P., Chitosan-alginate microcapsules for oral delivery of egg yolk immunoglobulin (IgY). J. Agric. Food Chem. 55 (2007), 2911–2917.
223. Yun, Y., Cho, Y.W., Park, K., Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65 (2013), 822–832.
224. Streit, M., Beleznay, Z., Braathen, L.R., Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int. Wound J. 3 (2006), 171–179.
225. Smola, M., Vandamme, T., Sokolowski, A., Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine 3 (2008), 1–19.
226. Koussoroplis, S.J., Paulissen, G., Tyteca, D., Goldansaz, H., Todoroff, J., Barilly, C., Uyttenhove, C., Van Snick, J., Cataldo, D., Vanbever, R., PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control. Release 187 (2014), 91–100.
227. Dellamary, L., Smith, D.J., Bloom, A., Bot, S., Guo, G.R., Deshmuk, H., Costello, M., Bot, A., Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J. Control. Release 95 (2004), 489–500.
228. Bot, A.I., Tarara, T.E., Smith, D.J., Bot, S.R., Woods, C.M., Weers, J.G., Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. 17 (2000), 275–283.
229. El-Sherbiny, I.M., El-Baz, N.M., Yacoub, M.H., Inhaled nano- and microparticles for drug delivery. Glob. Cardiol. Sci. Pract., 2015, 2015, 2.
230. Detalle, L., Stohr, T., Palomo, C., Piedra, P.A., Gilbert, B.E., Mas, V., Millar, A., Power, U.F., Stortelers, C., Allosery, K., Melero, J.A., Depla, E., Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 60 (2016), 6–13.